What is Psilera?
Psilera operates at the intersection of biotechnology and neuropharmacology, focusing on the repurposing of psychoactive natural products to create breakthrough medicines. The company distinguishes itself through a dual-pronged strategy: the development of novel chemical compounds and the utilization of a proprietary computational database designed to accelerate drug discovery. By integrating leadership expertise from both the pharmaceutical and cannabis sectors, Psilera maintains a patient-centric focus that aims to bridge the gap between traditional psychiatric care and modern, science-driven therapeutic interventions.
The firm's market position is bolstered by its commitment to regulatory compliance and high-fidelity research, allowing it to navigate the complex landscape of psychedelic medicine with institutional credibility. As the industry matures, Psilera's ability to synthesize natural product chemistry with computational modeling provides a distinct competitive advantage in the race to address unmet needs in mental health treatment.
How much funding has Psilera raised?
Psilera has raised a total of $11.3M across 2 funding rounds:
Angel/Seed
$2.5M
Seed
$8.8M
Angel/Seed (2021): $2.5M, investors not publicly disclosed
Seed (2026): $8.8M, investors not publicly disclosed
Key Investors in Psilera
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Psilera?
With this latest round of financing, Psilera is well-positioned to accelerate its clinical development programs and expand its computational research capabilities. The strategic allocation of these funds will likely focus on advancing its lead candidates through the regulatory pipeline and scaling its proprietary database infrastructure. As the company transitions from early-stage research to more advanced development phases, the focus will remain on validating the efficacy of its novel formulations in clinical settings.
Looking ahead, the firm is expected to deepen its partnerships within the pharmaceutical ecosystem, potentially seeking collaborative opportunities to bring its therapeutic innovations to market. The ongoing commitment to rigorous scientific inquiry, combined with the recent influx of capital, provides Psilera with the necessary runway to solidify its role as a key innovator in the evolving landscape of psychedelic-based medicine.
